Bevacizumab May Differentially Improve Prognosis of Advanced Ovarian Cancer Patients with Low Expression of VEGF-A165b, an Antiangiogenic VEGF-A Splice Variant.
Pauline WimbergerMara Julia GerberJacobus PfistererKati ErdmannSusanne FuesselTheresa LinkAndreas du BoisStefan KommossFlorian HeitzJalid SehouliRainer KimmigNikolaus de GregorioBarbara SchmalfeldtTjoung-Won Park-SimonKlaus BaumannFelix HilpertMarcel GrubeWillibald SchröderAlexander BurgesAntje BelauLars C HankerJan Dominik KuhlmannPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
We demonstrate for the first time that bevacizumab may differentially improve the prognosis of advanced ovarian cancer patients with low expression of VEGF-A165b, an antiangiogenic VEGF-A splice variant. We envision that this novel biomarker could be implemented into routine diagnostics and may have direct clinical implications for guiding bevacizumab-related treatment decisions in advanced ovarian cancer patients.